胆囊癌相关耐药基因及靶向治疗的研究进展

目的总结胆囊癌相关耐药基因及其靶向治疗的研究进展。方法收集国内外近年来有关胆囊癌相关耐药基因及其靶向治疗的文献并作综述。结果胆囊癌化疗耐药的机理主要涉及溶酶体蛋白跨膜p4抗体（LAP—TM4B）基因、核因子E2相关因子2（Nrf2）基因及肿瘤干细胞（CSCs）。胆囊癌治疗的基因靶点主要有LAPTM4B、Nemo样激酶（NLK）、组织因子途径抑制物．2（TFPI．2）、血管内皮生长因子-D（VEGF—D）、表皮生长因子受体（EGFR）及黑色素瘤分化相关基因一7／白介素．24（mda．7／IL．24）基因。结论胆囊癌相关耐药基因及其靶向治疗的研究均取得了一定的进展，拓宽了胆囊癌的传统治疗理念。

Research Progress of Resistance Genes and Targeted Therapy for Gallbladder Carcinoma

Objective To summarize the development of gallbladder carcinoma related resistance genes and targeted therapy. Methods Domestic and international publications online involving resistance genes and targeted therapy of gallbladder carcinoma in recent years were collected and reviewed. Results Recent studies had shown that chemotherapy drug resistance of gallbladder carcinoma mainly involved lysosome protein transmembrane [34 （LAPTM4B） gene, NF-E2-related factor 2 （Nrf2） gene, and cancer stem cells （CSCs）. While the latest gene targets of treatment for gallbladder carcinoma mainly involved LAPTM4B, Nemo-like kinase （NLK）, tissue factor way inhibitor-2 （TFPI-2）, vascular endothelial growth factor-D （VEGF-D）, epidermal growth factor receptor （EGFR）, and melanoma differentiation-associated gene 7/interleukin 24 （mda-7/IL-24） gene. Conclusion The research involving resistance genes and targeted therapy of gallbladder carcinoma has make a certain progress, which broaden the concept of traditional treatment of gallbladder carcinoma.